Table 1 Competing risk joint model results for the (A) longitudinal and (B) survival sub-model
A. Longitudinal sub-model | ||||
Longitudinal outcome | β3* (95% CI) | pVal | Intervention effect over 36 months (95% CI) | |
NTB 5-item composite (Z score) | 0.058 (0.023 to 0.094) | 0.001 | 0.175 (0.069 to 0.281) | |
NTB memory domain (Z score) | 0.074 (0.003 to 0.145) | 0.042 | 0.221 (0.008 to 0.434) | |
NTB executive function domain (Z score) | −0.006 (−0.064 to 0.052) | 0.828 | −0.019 (−0.193 to 0.155) | |
NTB total (Z score) | 0.024 (−0.019 to 0.067) | 0.278 | 0.071 (−0.058 to 0.200) | |
CDR-SB (score) | −0.295 (−0.480 to −0.109) | 0.002 | −0.884 (−1.440 to − 0.328) | |
MRI total hippocampal volume (cm3) | 0.071 (0.028 to 0.115) | 0.001 | 0.214 (0.084 to 0.344) | |
MRI whole brain volume (cm3) | 3.719 (0.829 to 6.609) | 0.012 | 11.157 (2.487 to 19.827) | |
MRI ventricular volume (cm3) | −0.659 (−1.426 to 0.108) | 0.092 | −1.978 (−4.279 to 0.324) | |
B. Survival sub-model | ||||
Longitudinal outcome | Missing group 1: open-label medication use | Missing group 2: dropout | ||
αGr1 | HR (95% CI) | αGr2 | HR (95% CI) | |
NTB 5-item composite (Z score) | −1.483 | 0.227 (0.164 to 0.315) | 1.266 | 3.548 (2.332 to 5.400) |
NTB memory domain (Z score) | −1.208 | 0.299 (0.216 to 0.414) | 1.094 | 2.987 (2.001 to 4.459) |
NTB executive function domain (Z score) | −0.711 | 0.491 (0.351 to 0.687) | 0.444 | 1.559 (1.000 to 2.429) |
NTB total (Z score) | −1.661 | 0.190 (0.123 to 0.294) | 1.373 | 3.947 (2.250 to 6.923) |
CDR-SB (score) | 0.497 | 1.644 (1.466 to 1.842) | −0.513 | 0.599 (0.501 to 0.715) |
MRI total hippocampal volume (cm3) | −0.530 | 0.588 (0.477 to 0.726) | 0.532 | 1.703 (1.299 to 2.232) |
MRI whole brain volume (cm3) | −0.002 | 0.998 (0.995 to 1.001) | 0.000 | 1.000 (0.996 to 1.004) |
MRI ventricular volume (cm3) | 0.013 | 1.013 (1.006 to 1.021) | −0.010 | 0.990 (0.980 to 1.000) |